A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

Part A: Inclusion Criteria:

• Subject has a body mass index (BMI) between ≥18.0 and <32.0 kg/m2

• In good health (as determined by the Investigator) based on medical history,physical examination, ECG, and clinical laboratory results.

• Female subjects must be non-pregnant and have a negative serum pregnancy test atScreening and a negative urine pregnancy test at Day-1 or Day 1 (predose).

• Agreement to comply with protocol-specified contraceptive requirements.

Part B: Inclusion Criteria:

• Subject has a body mass index (BMI) between ≥18.0 and <32.0 kg/m2

• Other than HSV infection, is in good health (as determined by the investigator)based on medical history, physical examination, ECG, and clinical laboratoryresults.

• Female subjects must be non-pregnant and have a negative serum pregnancy test atScreening and a negative urine pregnancy test at Day 1 (predose).

• Agreement to comply with protocol-specified contraceptive requirements

Part A and B: Exclusion Criteria:

• Current infection of human immunodeficiency virus (HIV), hepatitis B virus, (HBV),hepatitis C virus (HCV), acute hepatitis A virus (HAV), or acute hepatitis E virus (HEV).

• History of any illness that, in the opinion of the Investigator, might confound theresults of the study, pose an additional risk in administering study drug to thesubject, or condition known to interfere with the absorption /distribution/elimination of drugs.

• History of any significant drug-related allergic reactions such as anaphylaxis,Stevens-Johnson Syndrome, urticaria, or multiple drug allergies.

• History of persistent alcohol abuse or illicit drug abuse within 3 years prior toscreening.

• Has participated in a clinical study involving administration of either aninvestigational or a marketed drug within 30 days or 5 half-lives before screening,whatever is longer.